Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

NCT04676789 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG: Pegaspargase
DRUG: Anti-PD-1 monoclonal antibody
RADIATION: Definitive intensity-modulated radiotherapy (IMRT)

Sponsor

Sun Yat-sen University